eloralintide tirzepatide will be the obesity drug of the future. It will likely be approved to combine with other GLP-1 therapies to achieve greater results. A phase 3 trial for this is already Eli Lilly Obesity Drug: Eli

Altmed can discuss candidacy, medication safety, visit costs, prescription considerations, and next steps so patients understand the financial and medical side before committing

More research is needed to fully understand the effects of L-Carnitine on health

Most considerations of non-animal alternatives for skin irritation/sensitization testing tend to examine a single aspect of the process (e.g., chemical reactivity, epidermal bioavailability, dendritic cell responses)

The structural valve failure that causes varicose veins, spider veins, and chronic venous insufficiency does not reverse with weight loss alone, and GLP-1 medications are not a substitute for vein treatment

doi: 10.3389/fphys.2021.783396

The best place for it is the fridge